RxDoctor Payments DataLook up a doctor →

Ahmad Jabbar, MD

Interventional Cardiology · Harvey, LANPI 1023374451

Payments from drug & device makers

$55,343in general payments, 2019–2025

Across 348 payments — averaging $159.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$37K
  • Angiodynamics, Inc.$6K
  • Medtronic$4K
  • Penumbra, Inc.$2K
  • Inari Medical, Inc.$891
  • Novartis$542
  • plus $5K from 35 others

What the payments were for

  • Speaking & faculty fees$33,84561%
  • Travel & lodging$5,29210%
  • Food & beverage$11,39321%
  • Education$140%
  • Other$4,8009%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,343 in reported general payments places this provider in the 75th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$357,984
Medicare patients
322
Services billed
3,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban401$391,571
EntrestoSacubitril/Valsartan228$252,611
JardianceEmpagliflozin147$167,522
Repatha SureclickEvolocumab194$163,212
XareltoRivaroxaban153$144,696
OzempicSemaglutide39$53,758
FarxigaDapagliflozin Propanediol47$41,035
WegovySemaglutide20$26,286
BrilintaTicagrelor38$25,163
Praluent PenAlirocumab13$16,237
VascepaIcosapent Ethyl25$13,057
Repatha SyringeEvolocumab12$11,875
Repatha PushtronexEvolocumab13$11,385
Rosuvastatin Calcium397$5,022
Metoprolol Succinate382$4,339

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$390$391,571401 claims
NovartisEntresto$542$252,611228 claims
Boehringer IngelheimJardiance$115$167,522147 claims
Johnson & JohnsonXarelto$481$144,696153 claims
Novo NordiskOzempic, Wegovy$301$80,04459 claims
AstraZenecaFarxiga, Brilinta$282$66,19985 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Harvey

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →